Conditions: Lung Cancer
Keywords: Extensive Disease-Small Cell Lung Cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 300
Healthy volunteers: no

Brief summary:
This study drug(Amrubicin)is believed to work by stopping the tumor cell in your body from growing. The purpose of this study is to evaluate the efficacy and safety of amrubicin with cisplatin compared to etoposide-cisplatin in the first-line treatment in extensive disease small cell lung cancer The subject, who is randomized to AP group may be involved into a pharmacokinetic study of amrubicin and the metabolites: amrubicinol voluntarily.

Detailed description:

Arms:
arm 1: Amrubicin Hydrochloride-Cisplatin combined chemotherapy arm 2: Etoposide-Cisplatin combined chemotherapy

Interventions: intervention 1: Amrubicin Hydrochloride intervention 2: Etoposide-Cisplatin combined chemotherapy
Intervention descriptions: intervention 1: Amrubicin Hydrochloride combined with cisplatin intervention 2: combined chemotherapy

Protocol document: